It’s simple
to impact life

Booster Therapy - Spiral design balloon for the treatment of acute heart attacks

Top image
16 Milion

Around 16M people worldwide have a heart attack every year. Up to 30% of patients post Acute Myocardial Infarction (AMI) will develop heart failure which has a huge impact on morbidity and mortality

Booster
Booster device

Intratech is developing the Booster™ spiral balloon device for the treatment of AMI patients

Booster doctor

After the revascularization of the occluded artery, the Booster™ balloon is placed in the coronary sinus vein, and due to its unique spiral design, it increases the vascular pressure

Booster people

This elevated pressure enhances blood perfusion into the affected myocardium, improving the patient’s cardiac function

Advantages

Venous

Allowing continuous venous outflow

M yocardium

Redistribution of blood to the deprived myocardium

Microvascular

Improving microvascular perfusion

Deleterious

May enhance washout of deleterious agents

Vascular

May induce release of vascular growth factors

Branches

No obstruction of side branches

Boosting Cardiac Care

Intratech Medical is developing the Booster™ balloon catheter therapy for the treatment of patients with acute myocardial infarction, reducing infarct size and improving clinical outcomes.
About Boosting
About Booster
The Booster™ balloon revolutionizes the last frontier in ischemic heart disease management, improving the lives of millions of people worldwide, while decreasing related health care costs in a multibillion dollar market.

Intratech launched its first in human clinical study in 2022 with very promising results.
The company has secured a major investment from a key strategic corporation in the interventional cardiology field and has a comprehensive patent family with patents granted in the US, Canada, Europe, China, and Japan.

Prior to developing the Booster balloon, Intratech developed the NaviMax™ – a thrombectomy device for the treatment of ischemic stroke patients, which received CE mark.
About Company

Management

Linkedin
Moshe Barel, MSc

Moshe Barel, MSc
Chairman


X

Moshe has more than 15 years of experience in the medical device industry, having taken leadership roles within start-up companies and global corporates. Moshe is the founder and CEO of AccuLine and prior to that Moshe served in several companies – as the CEO of Intratech Medical, CEO at Sanolla, VP of Strategy at NovaSight, and business unit director at Lumenis and Johnson & Johnson. Moshe holds a BA in Economics AND Business Administration and an MSc in Business Administration – both from Tel-Aviv university.

Linkedin
Eran Hirszowicz, MSc

Eran Hirszowicz, MSc
Founder & CTO


X

Eran is a seasoned entrepreneur and inventor in the medical devices industry, with a proven track record in establishing successful medical device companies, with products that are in use today. Prior to founding Intratech Medical, Eran was the founder and CEO of GTI group, a medical device powerhouse with 3 subsidiaries: GTI-Medical, GTI-MD & GTI-Gali Tech, catering to start-ups and multinational corporations with product development, manufacturing and assembly services across the globe for over 20 years in numerous industries. Eran was also the founder & CTO of AngioSlide and EndoCross, startup companies developing solutions in endovascular and cardiology.

After his military service as Chief Machinery officer in the Israeli Navy (discharge as a Major), Eran established a factory for the production of optical elements. Eran holds an B.Sc. in Physics from the Technion – the Israel Institute of Technology and an M.Sc. in Biophysics from Tel Aviv University.  He holds 12 patents, with most implemented in existing products.

Linkedin
Prof. Giora Weisz, MD

Prof. Giora Weisz, MD
CMO


X

Prof. Weisz is an interventional cardiologist at Columbia University Medical Center in New York, an associate professor of medicine at Columbia University College of Physicians & Surgeons and a faculty member at the Cardiovascular Research Foundation.

Prof. Weisz is an internationally recognized researcher focused on innovative technologies in cardiovascular medicine. He has pioneered the use of novel robotic-enhanced coronary interventions, navigation and positioning technologies. Prof. Weisz has been the Principal Investigator for dozens of clinical studies – notably, with Mediguide which led to FDA approval and immediate acquisition of St Jude for 320M USD. He also consulted for SyncRx, influencing the system design which later led to acquisition by Volcano. Prof. Weisz was also a PI for the First-in-Human trial for the CorPath system which led to FDA approval resulting in an acquisition by Siemens for 1.1B USD. Prof. Weisz has published hundreds of papers in the most prestigious peer-reviewed medical journals, and is the author of dozens of articles, book chapters and other publications. He is an associate director of TCT – the premier interventional cardiology conference, and is a regular faculty member for the most important international cardiovascular meetings. Prof. Weisz serves as a reviewer for dozens of leading scientific journals and conferences. Prof. Weisz also serves on the editorial board of leading journals.

Scientific Advisors

Linkedin
Prof. Rafael Beyar

Prof. Rafael Beyar
M.D., D.Sc., M.P.H


X

Professor Rafael Beyar is an interventional cardiologist, a biomedical engineer and innovator. He is the former director of Rambam Health Care Campus and former Dean of the Faculty of Medicine at the Technion.

Prof. Beyar currently serves as a General Partner at Alive Health Care Fund and is the co-founder of the ICI – Innovation in Cardiovascular Interventions, a leading international cardiovascular meeting. His research focuses on cardiovascular robotics and imaging and coronary stents. He is the author of over 230 scientific publications and 15 books, is the recipient of numerous national and international awards and is the owner of multiple patents. Prof. Beyar founded Instent (acquired by Medtronic), Corindus (Acquired by Siemens), Rambam MedTech and MindUp Incubator (together with IBM, Medtronic, Pitango & Impact First), and serves as director and advisor for several start-up companies.

Linkedin
Dr. Timothy Henry

Dr. Timothy Henry
M.D.


X

Dr. Timothy D. Henry is the Medical Director of The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital in Cincinnati, Ohio, and the President of SCAI – The Society for Cardiovascular Angiography and Interventions. Prior to The Lindner Research Center, he was the Chief of Cardiology at Smidt Heart Institute at Cedars Sinai Medical Center and a Professor of Medicine at Cedars-Sinai and UCLA and the Director of Research at the Minneapolis Heart Institute Foundation, at Abbott Northwestern Hospital in Minneapolis and a Professor of Medicine at the University of Minneapolis.

Dr. Henry published over 600 manuscripts and book chapters and has served as principal investigator and steering committees of multiple large, multicenter research trials in acute myocardial infarction, refractory angina, and regenerative medicine with gene and stem cell therapy. He is the Principle Investigator for 2 large STEMI registries, The Midwest STEMI Consortium and the North American COVID STEMI registry. Among other awards, Dr. Henry has been named to the Best Doctors in America list each year for the last 15 years, received the American Heart Association’s Heart and Stroke Hero Award in Research, the LUMEN Global Lifetime Achievement Award in Myocardial Infarction, and most recently was awarded the Cincinnati 2021 Health Care Heroes Award, Innovator.

Get In Touch

    Country

    phone

    +972-9-9589-995

    location

    Shefayim Commercial Center
    Kibbutz Shefayim, 6099000
    Israel

    Linkedin
    Contact
    Skip to content